Skip to main content

Table 2 Target volume coverage and dose to organs at risk

From: Cone beam CT-based dose accumulation and analysis of delivered dose to the dominant intraprostatic lesion in primary radiotherapy of prostate cancer

 

Dose accumulation

Planned dose

p

PTVDIL

 D98% (Gy)

76.2 ± 1.6

75.6 ± 1.4

 < 0.001*

 D02% (Gy)

79.6 ± 1.5

79.1 ± 1.2

 < 0.001*

 D95% (Gy)

76.5 ± 1.5

75.9 ± 1.3

 < 0.001*

 DMean (Gy)

78.0 ± 1.4

77.4 ± 1.2

 < 0.001*

PTVBoost

 D98% (Gy)

71.1 ± 0.8

71.2 ± 0.7

0.750*

 D02% (Gy)

79.9 ± 0.8

79.4 ± 0.4

0.001

 D95% (Gy)

72.6 ± 0.7

72.5 ± 0.5

0.288

 DMean (Gy)

76.5 ± 0.6

76.1 ± 0.2

0.001*

PTV

 D98% (Gy)

57.5 ± 1.1

57.9 ± 0.7

0.129*

 D02% (Gy)

79.5 ± 0.8

79.0 ± 0.4

0.001

 D95% (Gy)

59.7 ± 0.8

59.6 ± 0.7

0.200

 DMean (Gy)

70.8 ± 1.3

70.4 ± 0.9

0.003

Rectum

 DMean (Gy)

23.4 ± 6.9

23.6 ± 6.6

0.353

Bladder

 DMean (Gy)

19.4 ± 7.4

18.8 ± 7.5

 < 0.001*

Femoral head left

 DMean (Gy)

16.1 ± 6.6

15.5 ± 6.4

0.001

Femoral head right

 DMean (Gy)

15.7 ± 5.0

14.8 ± 4.8

 < 0.001*

Penile bulb

 DMean (Gy)

29.1 ± 14.0

29.8 ± 14.4

 < 0.001

  1. Comparison between planned and accumulated dose for the target volumes and organs at risk. Statistical significance was tested by matched-pairs t-tests in case of normally distributed parameters. In case of non-normally distributed parameters Wilcoxon matched-pairs signed rank tests (*) were applied instead. Statistical significance was declared in case of a two-sided p < 0.05. Stated values indicate mean ± standard deviation
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us